Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States.
about
The History of Rubella and Rubella Vaccination Leading to EliminationVaccines for measles, mumps and rubella in childrenVaccines for measles, mumps and rubella in childrenNeutralizing activity in the gastrointestinal contents of piglets vaccinated with a live or formaldehyde-inactivated porcine enterovirusSang Froid in a time of trouble: is a vaccine against HIV possible?Rubella vaccination and thrombocytopenia.Effect of human leukocyte antigen homozygosity on rubella vaccine-induced humoral and cell-mediated immune responsesCorrelation between rubella antibody levels and cytokine measures of cell-mediated immunityHilary Koprowski and the viral immunity hub at the 1980s Wistar Institute: a T cell epitope perspective.Immunologic mechanisms responsible for adverse reactions to routine immunizations in children.Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination.Differences in Establishment of Persistence of Vaccine and Wild Type Rubella Viruses in Fetal Endothelial CellsAbsence of cell-mediated immunity to rubella virus 5 years after rubella vaccination.Prevention of congenital rubella.Antibody titres in women six to eight years after the administration of RA2713 and Cendehill rubella vaccines.Rubella in Orkney: seroepidemiology and vaccination.Persistence of antibody induced by rubella vaccine (Wistar RA 27/3 strain) after six years.Specific immunoglobulin responses in serum and nasal secretions after the administration of attenuated rubella vaccine.Rubella in the United States: toward a strategy for disease control and elimination.Rubella vaccines: past, present and future.Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals.Programmes for the prevention of rubella during pregnancy by active immunization.Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virusStability of the rabbit immunogenic marker of RA 27-3 rubella vaccine virus after human passage.Rubella vaccination: remaining problems.The administration of drugs and vaccines by the intranasal route.Long-term follow-up of women hospitalized for acute pyelonephritis.Duration of immunity conferred by rubella vaccines.RubellaVaccines for measles, mumps and rubella in children
P2860
Q24050084-30A41A7A-3F47-40D5-A7D9-177D82343E4DQ24203667-BF440712-2DD9-410C-BB5D-4454359D9BB3Q24245722-D8BCF2A1-1A7D-437D-A4EE-51266444253CQ27472694-9BDF4F27-DBAF-4D1F-ADC0-812D2672237EQ27487961-3859EBDF-E189-4CE3-BB8F-1B9740B9F0AAQ33464306-AD40990F-F27B-4487-867F-DC9FF6E0FBEEQ33625437-DCEAAD9D-9A62-4B8C-822B-51DD894874C0Q33701522-3D082ABE-B5AE-4B4A-A135-057EFB5B27E9Q33777386-803A4291-709F-4D79-8924-A0128BEFDBF2Q35234848-F93609F1-B6B5-4E69-B8E7-539B73732505Q35636074-2905CE1A-C910-4F43-BDFE-78289FD0FF3AQ35692318-1C806DD7-3835-43B7-9792-4DA5CCCB27B8Q35815571-D44107ED-365E-4B78-BD35-47AD50F8F078Q35816366-15BC2A45-A202-4E1F-80CC-EDE7F4352AFEQ36250789-FBDA4F0B-0388-4579-B141-93E75414EEDAQ36250919-5B30DBD3-1840-480C-8CFD-F6D17BABD74DQ36251791-6C01B011-35EC-4088-8D2C-9F52C55318CFQ36252158-9C155DBE-AE60-46EF-A8EB-46D09D5B478BQ36505672-137552C4-C2C8-4B90-B1FB-A636D547F286Q36505679-EF6ED38D-89D0-49AD-84EE-96A7E550BA7DQ36537843-A791A747-F7A5-4410-AD8B-7D155EBCCA56Q36678613-D8DD7238-7C98-4A51-B056-A68F09A32AE9Q37107211-7606D3B0-D57E-47D6-835F-DC848AD19AA3Q40879280-EBEA01D2-F205-466E-A95E-973309E52B67Q42336144-BD4E3D59-EE99-4EC3-A242-49FE8B2F7181Q43254619-EA097866-0545-4860-A579-3DF8ABD48C64Q44605669-C660F31D-7432-46A7-9FA3-2631E4904523Q54999188-EAA040E2-4F4B-4D4F-A0F4-A8783AEC5993Q55886053-B6C3043D-9F39-4FA0-8FE4-B0B3DDC10977Q57272255-2EA61570-4746-43D7-BC69-491339DF8200
P2860
Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States.
description
1973 nî lūn-bûn
@nan
1973年の論文
@ja
1973年学术文章
@wuu
1973年学术文章
@zh
1973年学术文章
@zh-cn
1973年学术文章
@zh-hans
1973年学术文章
@zh-my
1973年学术文章
@zh-sg
1973年學術文章
@yue
1973年學術文章
@zh-hant
name
Immunologic properties of RA27 ...... licensed in the United States.
@en
Immunologic properties of RA27 ...... licensed in the United States.
@nl
type
label
Immunologic properties of RA27 ...... licensed in the United States.
@en
Immunologic properties of RA27 ...... licensed in the United States.
@nl
prefLabel
Immunologic properties of RA27 ...... licensed in the United States.
@en
Immunologic properties of RA27 ...... licensed in the United States.
@nl
P921
P1476
Immunologic properties of RA27 ...... licensed in the United States.
@en
P2093
J D Farquhar
P304
P356
10.1001/JAMA.1973.03220330013003
P407
P577
1973-08-01T00:00:00Z